Last reviewed · How we verify
NCT07278609
The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions
trial testing MedSafer deprescribing opportunity reports, EMPOWER brochures in Rheumatic Diseases in 100 participants. Currently enrolling.
31 March 2028
Quick facts
| Lead sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 29 October 2025 |
| Primary completion | 31 March 2028 |
| Estimated completion | 30 June 2028 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- MedSafer deprescribing opportunity reports, EMPOWER brochures
Conditions studied
- Rheumatic Diseases — all drugs for Rheumatic Diseases →
- Inflammatory Arthritis — all drugs for Inflammatory Arthritis →
- Systemic Lupus Erthematosus (SLE) — all drugs for Systemic Lupus Erthematosus (SLE) →
- Vasculitis — all drugs for Vasculitis →
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Who can join
60 and older, any sex, with Rheumatic Diseases or Inflammatory Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
People with rheumatic conditions often take many medications, but more pills can increase the risk of side effects, especially in older adults. Some drugs (such as those intended to help pain or sleep) may cause more harm than good in the long term, and others may simply be no longer needed. These are known as 'potentially inappropriate medications' (PIMs). This quality improvement study focuses on people with rheumatic conditions aged 60 and over who take 5 or more daily medications. The goal of the study is to learn if a publicly available physician tool, MedSafer, combined with educational brochures (for patients), can help to reduce PIMs in this group. Researchers will follow participants during usual rheumatic disease care. They will compare the rate of PIM deprescribing (stopping medications or reducing the dose) before and after the introduction of the following 'bundle': * MedSafer reports provided to treating physicians * EMPOWER consumer brochures provided to patients Participants will be followed over 4 study visits (for 14-18 months) during which researchers will collect information on medication changes and serious adverse events (emergency visits or hospitalizations) and will complete questionnaires measuring quality of life.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07278609
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rheumatic Diseases
Currently open trials in the same condition.
- NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
- NCT07350395 — Exploring and Measuring the Impact of Steroids in Children and Young People · recruiting
- NCT07148414 — A Study of SPY072 in Rheumatic Disease · Phase 2 · recruiting
- NCT06400628 — Effectiveness of Chronic Self-management Education on Behavioral and Clinical Outcomes · NA · recruiting
- NCT05822219 — Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases · NA · active not recruiting
Other McGill University Health Centre/Research Institute of the McGill University Health Centre trials
Trials by the same sponsor.
- NCT07439406 — Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy · Phase 2 · not yet recruiting
- NCT07328971 — Vancomycin Taper to Prevent Recurrent Clostridioides Difficile · Phase 3 · not yet recruiting
- NCT07556952 — Dex & Mastectomy Pain · Phase 4 · recruiting
- NCT07069582 — Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women · Phase 1 · not yet recruiting
- NCT07386171 — Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07278609 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by McGill University Health Centre/Research Institute of the McGill University Health Centre
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07278609.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing